stock funds


Dear Evan Hansen of铿cially opened at the Music Box Theater on Dec. 4, moving to Broadway after a hugely successful run at the Second Stage Theater in New York earlier this year. With an impressive creative team, a bold, original new story and a wave of good buzz behind it, Dear Evan Hansen may become the next Broadway sensation and the season’s breakout hit.

Leading the cast is Ben Platt, giving a tour-de-force, breakthrough performance in the title role. Platt is best known for the Pitch Perfect 铿lms and has starred in The Book of Mormon. The show is directed by three-time Tony-winner Michael Greif, who also helmed the original productions of Rent and Next to Normal. The score is composed by the Tony-nominated team of Benj Pasek and Justin Paul (who’s work includes A Christmas Story: The Musical and the upcoming 铿lm La La Land) with orchestrations by Hamilton’s Tony-winning musical director Alex Lacamoire.

stock funds: TG Therapeutics, Inc.(TGTX)< /h3> Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

stock funds: USANA Health Sciences Inc.(USNA)


Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, non-cyclical consumer goods & services shares slipped by 0.33 percent. Meanwhile, top losers in the sector included Dr Pepper Snapple Group Inc. (NYSE: DPS), down 6 percent, and USANA Health Sciences, Inc. (NYSE: USNA), down 5 percent.

  • [By Peter Graham]

    A long term performance chart shows Herbalife Ltdand small capNu Skin Enterprises, Inc (NYSE: NUS) basically break even for long term investors whilesmall cap direct seller USANA Health Sciences, Inc (NYSE: USNA) had been a strong outperformer but has been moving sideways more recently:

  • [By Peter Graham]

    A long term performance chart shows Herbalife Ltdand small capNu Skin Enterprises, Inc (NYSE: NUS) back in positive territory whilesmall cap direct seller USANA Health Sciences, Inc (NYSE: USNA) had been a strong outperformer:

stock funds: American Woodmark Corporation(AMWD)

Advisors’ Opinion:

  • [By Lisa Levin]

    American Woodmark Corporation (NASDAQ: AMWD) was down, falling around 13 percent to $70.39 as the company reported weaker-than-expected quarterly earnings.

  • [By Lisa Levin]

    American Woodmark Corporation (NASDAQ: AMWD) was down, falling around 17 percent to $66.88 as the company reported weaker-than-expected quarterly earnings.

stock funds: Tantech Holdings Ltd.(TANH)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggestedshorting small cap China based carbon stock Tantech Holdings Ltd (NASDAQ: TANH):


    “The downtrend here is crystal clear; more of the same weakness is there on the earlier part of the chart you can’t see. What’s so compelling about the selloff is yesterday’s bar. The bulls tried to bounce back, but couldn’t… the buyers threw in the towel. TANH peeled back to close closer to the low than the high, and is following through — to the downside — today.”

stock funds: Rave Restaurant Group, Inc.(RAVE)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Rick Rouse]

    Rouse is sticking with his Best Stocks entry for this year’s competition. His selection is Rave Restaurant Group (RAVE), which owns Pie Five Pizza, a fast-casual pizza joint that Rouse thinks is changing the industry with its unique ovens.

    Says Rouse: “The company is on track to open 500 Pie Five locations over the next few years, and we are still in the early innings of this ballgame.” 

stock funds: The Advisory Board Company(ABCO)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Advisory Board (ABCO) on Friday reached a settlement with activist investor Elliott Management’s Paul Singer that ends the threat of a director battlefor nowas the healthcare technology and consulting firm continues to explore strategic alternatives, such as a sale.

Leave a Reply

Your email address will not be published. Required fields are marked *